Repurposing, repositioning - by whatever name, the 505(b)(2) drug development pathway is gaining traction. I will be giving a talk entitled “505(b)(2) Product Candidate Selection-Which Old Dog to Rejuvenate” on December 10 at the Drug Repurposing Strategies meeting. The conference costs $1695 but friends of Camargo can get a $400 discount - just contact me [...]
Search
About
You are currently browsing the Drug Kennel weblog archives for the month November, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.
Latest
- FDA’s DAARP is now DAAP, DPAP is now DPARP
- Exalgo Approved
- Do Not Neglect Your Third-Party Drug Substance Manufacturer
- Proposed FDA rule would make Sponsors more responsible for data integrity - way more responsible
- Spending on DTC Ads
- Generic Approvals Taking Longer
- Can and Should ANDA Labeling Differ from the RLD?
- Roche’s Actemra Approved For RA After Year’s Delay
- News on the Biosimilar Front
- Pediatric Assessments in Drug Development: timing in Europe vs. US
Medicaid paid for unapproved DESI drugs
Published November 25th, 2008 in News Commentary. 0 CommentsA minor ripple in the media, the Associated Press reviewed Medicaid records and found that since 2004, Medicaid has paid at least $200 million for unapproved drugs (perhaps $50MM per year). “Unapproved” sounds scary, right? These drugs are DESI drugs that are not normally reimbursed. $200 million pales in comparison to the amounts that Medicaid has paid. For [...]